Table 4.

Multivariable regression analyses on predictors of CINV in the very late period (days 6 to 21) in patients with a CR during the overall observation period

	Odds Ratioa	95% CI	P-value
Cycle 1 (n = 98)
Motion sickness	1.50	0.21; 10.9	0.687
Pregnancy-related morning sickness	0.40	0.05; 3.00	0.376
Alcohol intake (every day vs. none)	Not estimable	Not estimable	Not estimable
Age (≥50 vs. < 50 years)	0.69	0.10; 4.90	0.707
Nausea over last 24 h (0–10 NRS)	0.74	0.53; 1.03	0.077
Anxiety over last 24 h (0–10 NRS)	0.88	0.66; 1.17	0.390
Cycle 2 (n = 98)
Motion sickness	1.50	0.25; 9.07	0.660
Pregnancy-related morning sickness	0.51	0.10; 2.70	0.429
Alcohol intake (every day vs. none)	1.05	0.10; 11.6	0.968
Age (≥50 vs. < 50 years)	0.30	0.05; 1.86	0.197
Pre-chemotherapy nausea (0–10 NRS)	0.97	0.64; 1.47	0.870
Pre-chemotherapy anxiety (0–10 NRS)	0.92	0.65; 1.29	0.608
Cycle 3 (n = 100)
Motion sickness	0.44	0.10; 1.97	0.281
Pregnancy-related morning sickness	0.67	0.16; 2.87	0.589
Alcohol intake (every day vs. none)	Not estimable	Not estimable	Not estimable
Age (≥50 vs. < 50 years)	2.16	0.47; 9.94	0.323
Pre-chemotherapy nausea (0–10 NRS)	0.65	0.50; 0.85	0.001
Pre-chemotherapy anxiety (0–10 NRS)	0.88	0.68; 1.15	0.354
Cycle 4 (n = 96)
Motion sickness	0.11	0.01; 1.03	0.053
Pregnancy-related morning sickness	1.21	0.14; 10.6	0.862
Alcohol intake (every day vs. none)	0.77	0.04; 16.3	0.868
Age (≥50 vs. < 50 years)	0.11	0.01; 1.10	0.061
Pre-chemotherapy nausea (0–10 NRS)	0.50	0.34; 0.74	0.0006
Pre-chemotherapy anxiety (0–10 NRS)	1.16	0.78; 1.73	0.470

All patients received NEPA (netupitant/palonosetron) and dexamethasone on day 1 of each cycle; CINV chemotherapy-induced nausea and vomiting, CR complete response (no emesis and no use of rescue medication). CI confidence interval, NRS numeric rating scale (a score of 1 or greater indicating the occurrence of symptoms)

aOdds ratio lower than 1 indicates an increased likelihood of developing CINV events during the very late period